WHO Technical Report Series, No. 981 - World Health Organization

Acknowledgements
Agency, Inspection & Standards Division, London, England; Dr M. Mehmandoust,
Agence nationale de sécurité du médicament et des produits de santé, Saint-
Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines,
Medicines and Healthcare Products Regulatory Agency, London, England; Dr M.
Mikhail, Fresenius Kabi, Bad-Homburg, Germany; Dr J.H.McB. Miller,
Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control
Division, Danish Medicines Agency, Copenhagen, Denmark; Dr S. Mills,
Pharmaceutical Consultant, Ware, England; Ministry of Health, Muscat, Oman;
Ministry of Health, Government of Pakistan, Islamabad, Pakistan; Ministry of
Health and Welfare, Tokyo, Japan; Dr J. Mitchell, GlaxoSmithKline, Belgium;
Ms N. H. Mohd Potri, Senior Assistant, Director, GMP and Licensing Division,
Centre for Compliance and Licensing, National Pharmaceutical Control Bureau,
Ministry of Health Malaysia, Petaling Jaya, Malaysia; Dr J.A. Molzon, Associate
Director for International Programs, Center for Drug Evaluation and Research,
US Food and Drug Administration, Silver Spring, MD, USA; Dr I. Moore,
Product and Quality Assurance Manager, Croda Europe, Snaith, England; Dr J.
Morénas, Assistant Director, Inspection and Companies Department, Agence
nationale de sécurité du médicament et des produits de santé, Saint Denis, France;
Dr K. Morimoto, Expert, Office of Review Management, Review Planning
Division, Pharmaceutical and Medical Devices Agency, Tokyo, Japan; Dr O.
Morin, Regulatory and Scientific Affairs, International Federation of
Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr J.M.
Morris, Irish Medicines Board, Dublin, Ireland; Mr T. Moser, Galenica, Berne,
Switzerland; Dr A.E. Muhairwe, Executive Secretary and Registrar, National
Drug Authority, Kampala, Uganda; Dr. S. Mülbach, Director, Senior Regulatory
Counsellor, Vifor Pharma, Glattbrugg, Switzerland; Ms C. Munyimba-Yeta,
Director, Inspectorate and Licensing, Pharmaceutical Regulatory Authority,
Lusaka, Zambia; Ms N. Nan, Chief Pharmacist, National Institutes for Food and
Drug Control, Beijing, People’s Republic of China; Miss X. Nan, Project Officer,
China Center for Pharmaceutical International Exchange, Beijing, People’s
Republic of China; Dr E. Narciandi, Head, Technology Transfer Department,
Center for Genetic Engineering & Biotechnology, La Havana, Cuba; National
Agency of Drug and Food Control, Jakarta Pusat, Indonesia; National Authority
of Medicines and Health Products (INFARMED), Directorate for the Evaluation
of Medicinal Products, Lisbon, Portugal; National Institute of Drug Quality
Control of Vietnam, Hanoi, Viet Nam; Dr R. Neri, Sanofi, Antony, France; Dr E.
Nickličková, Inspector, State Institute for Drug Control, Prague, Czech Republic;
Professor A. Nicolas, Radiopharmacien, Expert analyse, Pharmacie, Hôpital
Brabois Adultes, Vandoeuvre, France; Dr H.K. Nielsen, Technical Specialist,
Essential Medicines, Medicines and Nutrition Centre, UNICEF Supply Division,
Copenhagen, Denmark; Dr K. Nodop, Inspections, European Medicines Agency,
London, England; Novartis Group, Novartis Campus, Basel, Switzerland;
53